KYTX vs. IOVA, VCEL, IMCR, RXRX, KYMR, BEAM, FUSN, NMRA, SANA, and VIR
Should you be buying Kyverna Therapeutics stock or one of its competitors? The main competitors of Kyverna Therapeutics include Iovance Biotherapeutics (IOVA), Vericel (VCEL), Immunocore (IMCR), Recursion Pharmaceuticals (RXRX), Kymera Therapeutics (KYMR), Beam Therapeutics (BEAM), Fusion Pharmaceuticals (FUSN), Neumora Therapeutics (NMRA), Sana Biotechnology (SANA), and Vir Biotechnology (VIR). These companies are all part of the "biological products, except diagnostic" industry.
Kyverna Therapeutics (NASDAQ:KYTX) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, profitability, valuation, institutional ownership, dividends, community ranking, risk and analyst recommendations.
Iovance Biotherapeutics received 555 more outperform votes than Kyverna Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Kyverna Therapeutics an outperform vote while only 74.57% of users gave Iovance Biotherapeutics an outperform vote.
In the previous week, Iovance Biotherapeutics had 1 more articles in the media than Kyverna Therapeutics. MarketBeat recorded 6 mentions for Iovance Biotherapeutics and 5 mentions for Kyverna Therapeutics. Iovance Biotherapeutics' average media sentiment score of 1.36 beat Kyverna Therapeutics' score of 0.26 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.
18.1% of Kyverna Therapeutics shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 10.4% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Kyverna Therapeutics presently has a consensus target price of $42.75, suggesting a potential upside of 216.20%. Iovance Biotherapeutics has a consensus target price of $24.64, suggesting a potential upside of 205.85%. Given Kyverna Therapeutics' higher probable upside, equities research analysts plainly believe Kyverna Therapeutics is more favorable than Iovance Biotherapeutics.
Kyverna Therapeutics has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -23,615.70%. Kyverna Therapeutics' return on equity of 0.00% beat Iovance Biotherapeutics' return on equity.
Kyverna Therapeutics has higher revenue and earnings than Iovance Biotherapeutics.
Summary
Kyverna Therapeutics and Iovance Biotherapeutics tied by winning 7 of the 14 factors compared between the two stocks.
Get Kyverna Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KYTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kyverna Therapeutics Competitors List
Related Companies and Tools
